Breast MRI using a high-relaxivity contrast agent: an overview.

OBJECTIVE The purpose of this article is to review the use of gadobenate dimeglumine, a high-relaxivity gadolinium-based contrast material, for breast MRI. CONCLUSION Thanks to its high relaxivity, gadobenate dimeglumine offers valuable advantages in terms of lesion conspicuity, detection rate, and sensitivity for malignant breast lesions. However, a higher enhancement of benign lesions should be taken into account to avoid reduced specificity.

[1]  H. Lusic,et al.  X-ray-computed tomography contrast agents. , 2013, Chemical reviews.

[2]  J. Szejnfeld,et al.  Analysis by MRI of residual tumor after radiofrequency ablation for early stage breast cancer. , 2012, AJR. American journal of roentgenology.

[3]  L. F. Serrano,et al.  Contrast media in breast imaging. , 2012, Magnetic resonance imaging clinics of North America.

[4]  N Houssami,et al.  Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. , 2012, Breast.

[5]  L. Martincich,et al.  Do we really need new contrast agents for MR-mammography? , 2012, European journal of radiology.

[6]  Roberto Orecchia,et al.  Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. , 2010, European journal of cancer.

[7]  F. Sardanelli,et al.  Handling a High Relaxivity Contrast Material for Dynamic Breast MR Imaging Using Higher Thresholds for the Initial Enhancement , 2010, Investigative radiology.

[8]  E. Morris.  Should we dispense with preoperative breast MRI? , 2010, The Lancet.

[9]  Andrew Hanby,et al.  Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial , 2010, The Lancet.

[10]  L. Solin.  Counterview: Pre-operative breast MRI (magnetic resonance imaging) is not recommended for all patients with newly diagnosed breast cancer. , 2010, Breast.

[11]  F. Sardanelli.  Overview of the role of pre-operative breast MRI in the absence of evidence on patient outcomes. , 2010, Breast.

[12]  R. Warren,et al.  Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Lenkinski,et al.  Interaction of gadolinium‐based MR contrast agents with choline: Implications for MR spectroscopy (MRS) of the breast , 2009, Magnetic resonance in medicine.

[14]  F. Podo,et al.  In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. , 2009, AJR. American journal of roentgenology.

[15]  P. Lewis,et al.  Role of breast MRI in the preoperative evaluation of patients with newly diagnosed breast cancer. , 2009, AJR. American journal of roentgenology.

[16]  F. Sardanelli,et al.  Contrast-enhanced breast MR imaging of claustrophobic or oversized patients using an open low-field magnet , 2009, La radiologia medica.

[17]  C. Catalano,et al.  Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine. , 2008, AJR. American journal of roentgenology.

[18]  A. Cilotti,et al.  Indications for breast magnetic resonance imaging. Consensus document “Attualità in senologia”, Florence 2007 , 2008, La radiologia medica.

[19]  Diego R Martin,et al.  Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.

[20]  A. Molen.  NEPHROGENIC SYSTEMIC FIBROSIS AND THE ROLE OF GADOLINIUM CONTRAST MEDIA , 2008 .

[21]  Les Irwig,et al.  Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Marie-France Bellin,et al.  Extracellular gadolinium-based contrast media: an overview. , 2008, European journal of radiology.

[23]  D. Broome,et al.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.

[24]  Francesco Sardanelli,et al.  Gadobenate Dimeglumine as a Contrast Agent for Dynamic Breast Magnetic Resonance Imaging: Effect of Higher Initial Enhancement Thresholds on Diagnostic Performance , 2008, Investigative radiology.

[25]  H. Hussain,et al.  Nephrogenic systemic fibrosis: a report of 29 cases. , 2008, AJR. American journal of roentgenology.

[26]  W. B. Veldhuis,et al.  Contrast-enhanced 3.0-T breast MRI for characterization of breast lesions: increased specificity by using vascular maps , 2008, European Radiology.

[27]  Wei Huang,et al.  Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. , 2007, Radiology.

[28]  C. Kuhl.  Current status of breast MR imaging. Part 2. Clinical applications. , 2007, Radiology.

[29]  C. Kuhl.  Breast MR imaging at 3T. , 2007, Magnetic resonance imaging clinics of North America.

[30]  C. Kuhl.  The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. , 2007, Radiology.

[31]  C. Catalano,et al.  Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions. , 2007, Radiology.

[32]  C. Gatsonis,et al.  MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. , 2007, The New England journal of medicine.

[33]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[34]  C. Catalano,et al.  Contrast-enhanced magnetic resonance mammography: does it affect surgical decision-making in patients with breast cancer? , 2007, Breast Cancer Research and Treatment.

[35]  Jürgen Gieseke,et al.  Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. , 2006, Radiology.

[36]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  I. Wilkinson,et al.  Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast Agents , 2006, Investigative radiology.

[38]  F. Schick,et al.  Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla , 2006, Investigative radiology.

[39]  J. Mintorovitch,et al.  Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.

[40]  C. Catalano,et al.  Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. , 2005, Radiology.

[41]  Hans H Schild,et al.  Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. , 2005, Radiology.

[42]  Alessandro Carriero,et al.  Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. , 2005, Radiology.

[43]  V. Runge,et al.  Contrast Agents for Magnetic Resonance Imaging: Safety Update , 2003, Topics in magnetic resonance imaging : TMRI.

[44]  M. Oudkerk,et al.  Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. , 2003, AJR. American journal of roentgenology.

[45]  N. Hylton.  Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast. , 2003, AJR. American journal of roentgenology.

[46]  P. Choyke,et al.  Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.

[47]  Mitchell D Schnall,et al.  MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. , 2003, Radiology.

[48]  Jennifer B Kaplan,et al.  MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. , 2003, AJR. American journal of roentgenology.

[49]  F. Sardanelli,et al.  Contrast agents and temporal resolution in breast MR imaging. , 2002, Journal of experimental & clinical cancer research : CR.

[50]  L. Bonomo,et al.  Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. , 2002, Journal of experimental & clinical cancer research : CR.

[51]  R. Lenkinski,et al.  Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. , 2002, Journal of the National Cancer Institute.

[52]  J. K. Smith,et al.  Effects of contrast material on single-volume proton MR spectroscopy. , 2000, AJNR. American journal of neuroradiology.

[53]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[54]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[55]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[56]  S. Heywang-Köbrunner,et al.  Contrast-Enhanced MRI of the Breast , 1991 .

[57]  S. Heywang,et al.  MR imaging of the breast using gadolinium-DTPA. , 1986, Journal of computer assisted tomography.

[58]  Bernd Hamm,et al.  Gadolinium-enhanced MR angiography of the breast: Is breast cancer associated with ipsilateral higher vascularity? , 2001, European Radiology.

[59]  L. Banci.  Nuclear and electron relaxation , 1991 .